INNEXUS BIOTECHNOLOGY GETS PATENT GRANTS IN EUROPE

摘要

InNexus Biotechnology Inc.,(OTC Bulletin Board:IXSBF;TSX VENTURE:IXS),British Columbia,Canada,a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking(DXL(TM))technology,has received patent grants in Germany,Spain,France,Great Britain and Italy further expanding patent protection of its DXL(TM)technology in Europe.The patents,titled"METHOD OF AFFINITY CROSS-LINKING BIOLOGICALLY ACTIVE,IMMUNOGENIC PEPTIDES TO ANTIBODIES,"relate to the company's ability to create,develop and manufacture antibodies based on its DXL(TM)technology platform.The new patents name InNexus scientists as inventors and are solely owned by InNexus.